Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

Pablo Altman1*, Luis Wehbe2, Juergen Dederichs3, Tadhg Guerin4, Brian Ament5, Miguel Cardenas Moronta3, Andrea Valeria Pino6 and Pankaj Goyal3

Abstract

Background: The chronic and progressive nature of chronic obstructive pulmonary disease (COPD) requires self-administration of inhaled medication. Dry powder inhalers (DPIs) are increasingly being used for inhalation therapy in COPD. Important considerations when selecting DPIs include inhalation effort required and flow rates achieved by patients. Here, we present the comparison of the peak inspiratory flow rate (PIF) values achieved by COPD patients, with moderate to very severe airflow limitation, through the Breezhaler®, the Ellipta® and the HandiHaler® inhalers. The effects of disease severity, age and gender on PIF rate were also evaluated.

Methods: This randomized, open-label, multicenter, cross-over, Phase IV study recruited patients with moderate to very severe airflow limitation (Global Initiative for Obstructive Lung Disease 2014 strategy), aged ≥40 years and having a smoking history of ≥10 pack years. No active drug or placebo was administered during the study. The inhalation profiles were recorded using inhalers fitted with a pressure tap and transducer at the wall of the mouthpiece. For each patient, the inhalation with the highest PIF value, out of three replicate inhalations per device, was selected for analysis. A paired t-test was performed to compare mean PIFs between each combination of devices.

Results: In total, 97 COPD patients were enrolled and completed the study. The highest mean PIF value (L/min ± SE) was observed with the Breezhaler® (108 ± 23), followed by the Ellipta® (78 ± 15) and the HandiHaler® (49 ± 9) inhalers and the lowest mean pressure drop values were recorded with the Breezhaler® inhaler, followed by the Ellipta® inhaler and the HandiHaler® inhaler, in the overall patient population. A similar trend was consistently observed in patients across all subgroups of COPD severity, within all age groups and for both genders.

Conclusions: Patients with COPD were able to inhale with the least inspiratory effort and generate the highest mean PIF value through the Breezhaler® inhaler when compared with the Ellipta® and the HandiHaler® inhalers. These results were similar irrespective of patients’ COPD severity, age or gender.

Trial registration: The trial was registered with ClinicalTrials.gov NCT02596009 on 4 November 2015.

Keywords: Peak inspiratory flow, Inspiratory effort, Dry powder inhalers, Pressure drop, Breezhaler®
Background
The progressive nature of chronic obstructive pulmonary disease (COPD), characterised by persistent airflow obstruction, necessitates regular self-administration of inhaled medications that are delivered directly to the desired site to relieve symptoms while minimizing systemic side effects [1]. Clinical trial and real-world study data provide conclusive evidence enabling physicians to make informed decisions about choice of medication [1]; however, little consideration is given to attributes of the inhaler and patients’ ability to use them [2], especially in elderly patients or those with severe disease [3]. The recently updated Global Initiative for Obstructive Lung Disease (GOLD) strategy document has taken a step towards reaching a consensus on considerations for ensuring effectiveness of the inhaled treatment [1]. However, there still seems to be a lack of agreement on considerations involved in choosing an appropriate inhaler.

A large variety of inhalers are currently available, each offering distinct advantages and disadvantages. Most metered-dose inhalers (MDIs) are not breath-actuated and use a pressurized propellant to deliver the drug, which means that less inspiratory effort is required. However, it is sometimes difficult for the patient to synchronize inhalation and actuation when using MDI devices [4, 5].

In contrast, breath-actuated dry powder inhalers (DPIs) [6] rely, amongst other factors, on the patient’s ability to produce sufficient airflow [7]. Each DPI has an intrinsic resistance that affects the inspiratory effort needed to effectively inhale the drug from the device [8]. The inspiratory maneuver of the patient creates a pressure differential within a DPI (reflective of the patient’s inspiratory effort), driving the airflow, which also depends on the intrinsic airflow resistance of the inhaler [9]. Inhalers with low airflow resistance allow air to flow through them more easily and are, therefore, more likely to allow the patients to inhale with a lower effort [10, 11] compared with higher resistance inhalers that require forceful inhalation [9]. An important consideration when choosing an inhaler, therefore, should be the ease associated with the inhalation effort required to take the medication [10]. Inhalation effort assumes even greater importance for COPD patients with muscular weakness, since ability to generate higher flow rates comfortably might be compromised, especially in patients with severe and very severe airflow limitation [9].

The Breezhaler® inhaler is a unit-dose, capsule-based DPI that has low internal (airflow) resistance [12, 13] is easy to use correctly, delivers a consistent dose of inhaled medication across different inhalation flow rates [14–17] and was suggested previously, through in-vitro studies, to require lower inhalation effort [10].

The objective of this study was to compare the peak inspiratory flow rate (PIF) values generated by patients with COPD through three different types of DPIs, the Breezhaler®, the Ellipta® and the HandiHaler®. The effects of disease severity, age and gender on PIF values generated through these inhalers were also evaluated.

Methods
Study design
This was a multicenter, open-label, randomized, cross-over, Phase IV study conducted across five sites in Argentina from 16 December 2015 to 29 April 2016 in COPD patients with moderate, severe, or very severe airflow limitation (GOLD 2014) [18]. There were two visits in the study: one for screening and the second for testing procedures (Fig. 1). The three inhalers tested in this study were the Breezhaler® (B), Ellipta® (E) and HandiHaler® (H) inhalers. No active drug or placebo was administered to patients during the study; the Breezhaler® and HandiHaler® inhalers with closed empty clear hydroxypropyl methylcellulose capsules were provided to each site and pierced just before inhalation measurements. The drug containing blister strips of Ellipta® were replaced by empty strips during device preparation by the investigator (Novartis). The inhalers were modified using a pressure tap and transducer fitted at

![Fig. 1 Study design. *Sequence of testing via inhaler 1, 2 and 3 for each patient will depend on randomization](image-url)
the wall of the mouthpiece. The inhalational measurement method has been tested and validated by measurement of the airflow resistance of each device before and after the modification with the pressure tap. The airflow resistance was confirmed as unchanged due to the modification.

Patients inhaled through the three DPIs following a randomized cross-over sequence (6 sequences used were: BEH, EHB, HBE, BHE, EBH and HEB). Before inhalation, patients were trained on use of each inhaler by the study personnel. A standard ‘Investigator’s Test Script’ was used across all sites to standardize the inhalation maneuver. Each patient was required to record three inhalation profiles via each inhalation device. Patients were allowed to rest between successive inhalations from the same device, and between inhalations from two different devices. The highest PIF value, of the three replicate inhalations per device, was used for the analyses. A custom-built and calibrated inhalation profile recorder (IPR; The Technology Partnership, UK) was used to measure and record patients’ inspiratory flow rates. Each inhaler was modified at the mouthpiece with a small stainless steel tube to connect to the IPR pressure transducer. The inhalers were characterized before the start of the study to ensure a specific pressure drop and the airflow through the device was comparable before and after attaching the instrumentation. Further, they were sanitized and packed for the study. Each device was given a unique identification number and label that were recorded in the case report form. During patient inhalation, the IPR measured the mouthpiece pressure drop, converted it into flow rate using inhaler resistance and plotted the results on the graphic–user interface (GUI) (Fig. 2). The PIF value was determined by the IPR software as the highest flow rate achieved by the patient and displayed on the GUI. The highest PIF value out of the three repeat runs per patient and per inhaler was used in the data analysis. Inhalation profiles were plotted using custom Matlab script according to the inhaler used and the subgroups: gender, age, and COPD severity, and manually reviewed.

**Ethics approval and consent to participate**
The study protocol was reviewed by the institutional review boards and ethics committees for each center (list included in Additional file 1). The study was conducted according to the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from each patient prior to performing any study related assessment.

**Participants**
The study included men and women aged ≥40 years, diagnosed with moderate, severe, or very severe COPD, i.e. airflow limitation with post-bronchodilator forced expiratory volume in 1 s (FEV₁) < 80% of predicted normal and FEV₁/forced vital capacity < 0.70 at time of screening (GOLD 2014) [18]. Participants were current or ex-smokers with a smoking history of ≥10 pack years.

Patients were excluded if they experienced a COPD exacerbation that required treatment with antibiotics or oral corticosteroids or hospitalization within 6 weeks prior to screening, or had a respiratory tract infection within 4 weeks prior to screening, or had a history of asthma or onset of respiratory symptoms prior to the age of 40 years. Patients were also excluded if they were unable to use any of the three test inhalers due to cognitive impairment, neurological disorders, or any other condition affecting use of the DPIs.

**Study objectives**
The primary objective of the study was to compare the PIF values generated by patients with moderate, severe, or very severe airflow obstruction through the Breezhaler®, Ellipta® and HandiHaler® DPIs. Exploratory objectives included assessing the effect of age, gender and disease severity on the PIF values generated through the three DPIs. Additional analyses included comparison of the pressure drop at PIF (as a measure of inspiratory effort) across all devices as a function of COPD severity, age (40–64, 65–74 and ≥75) and gender.
**Assessments**

Raw data included the pressure drop values, and flow rate was calculated using the equation:

$$\sqrt{\Delta P} = Q \times R$$

where $$\Delta P$$ (kPa) is the pressure drop observed in the inhaler, $$Q$$ (L/min) is the inhalation flow and $$R$$ (cmH$_2$O$^{0.5}$/[L/min]$^{-1}$) is the airflow resistance [9]. To convert pressure drop to flow rate, previously published 'measured internal resistance' values for Breezhaler®, Ellipta® and HandiHaler® inhalers (i.e. 0.060, 0.090 and 0.163 cmH$_2$O$^{0.5}$/[L/min]$^{-1}$ [19, 20]) respectively, were used. Pressure drops at PIF were compared between the three inhalers as a function of COPD severity, age and gender. Safety was evaluated based on the incidence rate of adverse events (AEs), vital signs, and physical examination.

**Statistical analysis**

The full analysis set consisted of all 97 patients who conducted an inhalation maneuver through at least one inhaler. Profiles containing constant pressure values, termed 'flat lines', evaluated as incorrect profiles, were not considered in the final analysis. P-values were generated using a paired t-test with $$P < 0.01$$ indicating a significant difference which controls the familywise type 1 error rate at 3% under multiple testing for the primary PIF analysis on the FAS. P-values for subgroup analysis are exploratory in nature.

**Sample size**

A six-sequence Williams design was used to calculate the sample size. This design and an assumed standard deviation (SD) of 17.7 L/min (calculated according to previous findings) and a sample size of 96 patients (16 in each of the six possible sequences, i.e. 16 × 6 = 96) had > 90% power to detect a difference in PIF values between a pair of inhalers of 10 L/min (2-sided alpha 0.05).

**Results**

**Participants**

A total of 97 patients with a mean ± SD age of 69.0 ± 8.2 years enrolled and completed the study. Almost all patients were Caucasians and the majority of the population was male. The majority of patients had either moderate or severe COPD with mean ± SD time since diagnosis of 8.2 ± 4.2 years (Table 1). Overall, 15.5% of patients had experienced a COPD exacerbation in the previous year.

**PIF values and pressure drop**

In the overall population, patients produced the highest mean PIF values with the Breezhaler® inhaler followed by the Ellipta® and the HandiHaler® inhalers. The lowest mean pressure drop values were recorded with the Breezhaler® inhaler, again followed by the Ellipta® inhaler and the HandiHaler® inhaler (Table 2).

**Table 1** Baseline demographics and clinical characteristics (Full analysis set)

| Characteristic | Value (N = 97) |
|---------------|---------------|
| Age, years    | 69.0 ± 8.2    |
| Male, n (%)   | 72 (74.2)     |
| Race, n (%)   |              |
| Caucasian     | 96 (99.0)     |
| Asian         | 1 (1.0)       |
| BMI (kg/m²)   | 27.0 ± 5.3    |
| Current smoker, n (%) | 14 (14.4) |
| Severity of COPD, n (%) |     |
| Moderate      | 49 (50.5)     |
| Severe        | 38 (39.2)     |
| Very severe   | 10 (10.3)     |
| Number of COPD exacerbations in the previous year | 0.2 ± 0.51 |
| Post-bronchodilator FEV$_1$, % predicted | 50.7 ± 15.5 |
| Post-bronchodilator (%) FEV$_1$/FVC | 48.3 ± 11.3 |

Data are presented as mean ± standard deviation, unless otherwise specified. COPD severity is based on GOLD 2014 criteria. BMI body mass index, FEV$_1$ forced expiratory volume in 1 s, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease.

**Subgroup analysis by severity of COPD**

The results observed across all COPD severities were in line with the overall population; i.e. patients of all subgroups produced highest mean PIF values with the Breezhaler® compared with the Ellipta® and the HandiHaler® inhalers. The lowest mean pressure drop values were observed for the Breezhaler® followed by the Ellipta® and the HandiHaler® inhalers (Table 3). For each inhaler, the mean PIF values were similar for patients with moderate and severe COPD, but lower for patients with very severe COPD (Table 3).

**Subgroup analysis by age**

Results observed across all age groups were also consistent with the overall results. Irrespective of age group, patients produced highest mean PIF values with the Breezhaler® versus the Ellipta® and the HandiHaler® inhalers, and the lowest mean pressure drop values were recorded for the Breezhaler® versus the Ellipta® and the HandiHaler® inhalers (Table 4). Across all inhalers, patients aged 40–64 years generated the highest mean PIF values, while patients aged ≥75 years generated mean PIF values comparable with those aged 65–74 years (Table 4).

**Subgroup analysis by gender**

Similar to the overall results, both male and female patient populations produced the highest mean PIF values with the Breezhaler® compared with the Ellipta® and the HandiHaler® inhalers. The lowest mean
pressure drop values were observed for the Breezhaler® versus the Ellipta® and the HandiHaler® inhalers, irrespective of gender (Table 5). Irrespective of the inhaler used, the PIF values observed for females were consistently lower than those observed for males (Table 5).

**Safety**

No AEs or serious AEs were reported in this study. No clinically significant observations were observed with regards to changes in vital signs.

**Discussion**

The clinical relevance of inhaled therapy relies on its ability to deliver drug directly to the intended site and avoiding systemic side effects [1]. While identifying the most appropriate treatment, health-care professionals are often more focused on pharmacological properties of a drug and tend to overlook, that inhaler characteristics may have an impact on the overall treatment benefit [21]. Patients’ inhalation flow pattern can significantly influence the performance of an inhaler, thus impact effectiveness of the inhalation therapy [22]. However, there is limited data available comparing the inspiratory flow

### Table 2 Comparison of mean PIF and pressure drop values in overall population

| Variable                  | Breezhaler® | Ellipta® | HandiHaler® |
|---------------------------|-------------|----------|-------------|
| n                         | 97          | 91       | 97          |
| R (cmH$_2$O$^{0.5}$[L/min]$^{-1}$) | 0.060      | 0.090    | 0.163       |
| PIF (L/min)               | 108 ± 23    | 78 ± 15  | 49 ± 9      |
| Range (Min–Max)           | 54–156      | 45–109   | 22–70       |
| Pressure drop at PIF (cmH$_2$O) | 44 ± 18    | 51 ± 19  | 67 ± 23     |
| ΔPIF vs Breezhaler® (L/min); 95% CI | –          | 30; 27 to 32 | 59; 56 to 62 |
| P-value                   | < 0.0001    | < 0.0001 |             |

Data are presented as mean ± standard deviation unless stated otherwise. P-values generated from a paired t-test on comparison of PIF values. CI confidence interval, n number of patients, ΔPIF difference in mean PIF values, PIF peak inspiratory flow rate, R intrinsic airflow resistance of the inhaler

aData published previously [19, 20]

### Table 3 Comparison of mean PIF and pressure drop values based on severity of COPD

| Severity | Variable                  | Breezhaler® | Ellipta® | HandiHaler® |
|----------|---------------------------|-------------|----------|-------------|
|          | n                         | 49          | 44       | 49          |
| Moderate | PIF (L/min)               | 109 ± 26    | 78 ± 15  | 50 ± 10     |
|          | Range (Min–Max)           | 54–152      | 45–102   | 22–68       |
|          | Pressure drop at PIF (cmH$_2$O) | 45 ± 20    | 52 ± 19  | 68 ± 25     |
|          | ΔPIF vs Breezhaler® (L/min); 95% CI | –          | 31; 26 to 34 | 59; 54 to 64 |
|          | P-value                   | < 0.0001    | < 0.0001 |             |
| Severe   | n                         | 38          | 37       | 38          |
|          | PIF (L/min)               | 110 ± 22    | 79 ± 15  | 49 ± 8      |
|          | Range (Min–Max)           | 71–156      | 48–109   | 31–70       |
|          | Pressure drop at PIF (cmH$_2$O) | 45 ± 17    | 53 ± 19  | 67 ± 22     |
|          | ΔPIF vs Breezhaler® (L/min); 95% CI | –          | 31; 26 to 33 | 61; 55 to 65 |
|          | P-value                   | < 0.0001    | < 0.0001 |             |
| Very severe | n                        | 10          | 10       | 10          |
|          | PIF (L/min)               | 99 ± 14     | 71 ± 13  | 46 ± 7      |
|          | Range (Min–Max)           | 77–128      | 52–102   | 33–59       |
|          | Pressure drop at PIF (cmH$_2$O) | 36 ± 10    | 42 ± 17  | 58 ± 17     |
|          | ΔPIF vs Breezhaler® (L/min); 95% CI | –          | 28; 24 to 32 | 53; 46 to 60 |
|          | P-value                   | < 0.0001    | < 0.0001 |             |

Data are presented as mean ± standard deviation unless stated otherwise. P-values for subgroup analysis are exploratory in nature. Poor quality (flat-line) inhalational profiles with erroneous PIF values were not considered in the analysis. CI confidence interval, n number of patients, ΔPIF difference in mean PIF values, PIF peak inspiratory flow rate, R intrinsic airflow resistance of the inhaler

aData published previously [19, 20]
rates of the marketed products [17]. Our study provides
direct comparison of inspiratory flows achieved by COPD
patients between the three widely used dry powder in-
halers i.e. the Breezhaler®, the Ellipta® and the HandiHaler®
with varying internal resistance.

It is important to assess patients’
characteristics when
prescribing the medication. Patient characteristics such as
age, gender and disease severity can affect the perform-
ance of the inhalers; studies have reported that increasing
age [23] and COPD severity [24], may reduce patients’

Table 4 Comparison of mean PIF and pressure drop values based on age

| Age (years) | Variable | Breezhaler* | Ellipta* | HandiHaler* |
|-------------|----------|-------------|----------|-------------|
|             | R (cmH2O0.5[L/min]−1) | 0.060 | 0.090 | 0.163 |
| 40–64       | n        | 27 | 27 | 27 |
|             | PIF (L/min) | 123 ± 20 | 88 ± 13 | 53 ± 9 |
|             | Range (Min-Max) | 77–156 | 57–109 | 32–70 |
|             | Pressure drop at PIF (cmH2O) | 56 ± 17 | 64 ± 18 | 76 ± 23 |
|             | ΔPIF vs Breezhaler* (L/min); 95% CI | – | 35; 30 to 40 | 70; 65 to 76 |
|             | P-value | – | < 0.0001 | < 0.0001 |
| 65–74       | n        | 46 | 42 | 46 |
|             | PIF (L/min) | 101 ± 22 | 73 ± 13 | 47 ± 9 |
|             | Range (Min-Max) | 54–152 | 48–99 | 22–68 |
|             | Pressure drop at PIF (cmH2O) | 38 ± 16 | 45 ± 16 | 61 ± 23 |
|             | ΔPIF vs Breezhaler* (L/min); 95% CI | – | 28; 23 to 30 | 54; 49 to 58 |
|             | P-value | – | < 0.0001 | < 0.0001 |
| ≥75         | n        | 24 | 22 | 24 |
|             | PIF (L/min) | 105 ± 21 | 75 ± 16 | 50 ± 9 |
|             | Range (Min-Max) | 65–151 | 45–102 | 29–66 |
|             | Pressure drop at PIF (cmH2O) | 41 ± 17 | 48 ± 18 | 67 ± 22 |
|             | ΔPIF vs Breezhaler* (L/min); 95% CI | – | 30; 24 to 35 | 55; 49 to 62 |
|             | P-value | – | < 0.0001 | < 0.0001 |

Data are presented as mean ± standard deviation unless stated otherwise. P-values for subgroup analysis are exploratory in nature.

CI confidence interval, n number of patients, ΔPIF difference in mean PIF values, PIF peak inspiratory flow rate, R intrinsic airflow resistance of the inhaler

Poor quality (flat-line) inhalational profiles with erroneous PIF values were not considered in the analysis.

aData published previously [19, 20]

Table 5 Comparison of mean PIF and pressure drop values based on gender

| Gender | Variable | Breezhaler* | Ellipta* | HandiHaler* |
|--------|----------|-------------|----------|-------------|
|        | R (cmH2O0.5[L/min]−1) | 0.060 | 0.090 | 0.163 |
| Male   | n        | 72 | 68 | 72 |
|        | PIF (L/min) | 111 ± 24 | 81 ± 16 | 51 ± 9 |
|        | Range (Min-Max) | 54–156 | 45–109 | 22–70 |
|        | Pressure drop at PIF (cmH2O) | 47 ± 19 | 54 ± 20 | 71 ± 23 |
|        | ΔPIF vs Breezhaler* (L/min); 95% CI | – | 30; 28 to 34 | 60; 57 to 65 |
|        | P-value | – | < 0.0001 | < 0.0001 |
| Female | n        | 25 | 23 | 25 |
|        | PIF (L/min) | 98 ± 15 | 71 ± 11 | 45 ± 8 |
|        | Range (Min-Max) | 71–121 | 49–89 | 32–57 |
|        | Pressure drop at PIF (cmH2O) | 36 ± 11 | 41 ± 12 | 56 ± 20 |
|        | ΔPIF vs Breezhaler* (L/min); 95% CI | – | 27; 23 to 31 | 53; 49 to 57 |
|        | P-value | – | < 0.0001 | < 0.0001 |

Data are presented as mean ± standard deviation unless stated otherwise. P-values for subgroup analysis are exploratory in nature.

CI confidence interval, n number of patients, ΔPIF difference in mean PIF values, PIF peak inspiratory flow rate, R intrinsic airflow resistance of the inhaler

Poor quality (flat-line) inhalational profiles with erroneous PIF values were not considered in the analysis.

aData published previously [19, 20]
Inhalation capability. Mahler et al. observed that suboptimal PIF values were predominantly exhibited by female patients when using DPI [25].

In this study, COPD patients produced the highest mean PIF rate when inhaling through the Breezhaler® inhaler compared with the Ellipta® and the HandiHaler® inhalers. Correspondingly, the lowest mean pressure drop was recorded when patients were using the Breezhaler® inhaler versus the Ellipta® or the HandiHaler® inhalers. This confirmed the prior knowledge that for a set inspiratory effort, the inhalation flows when using a low resistance DPI are expected be greater than when using a DPI with a higher resistance [26].

The mechanism of breath actuation in DPIs requires patients to generate airflow against the intrinsic airflow resistance of the inhaler. The reliance on patient-generated flow rate for effective inhalation can be minimized when using an inhaler with low intrinsic airflow resistance [11], so that patients need to exert lower inspiratory effort to generate sufficient and sustained airflow [8]. In this study, patients required least inspiratory effort when inhaling through the Breezhaler® compared with the Ellipta® and the HandiHaler® DPIs, suggesting that patients can inhale more comfortably though low resistance Breezhaler® inhaler. The results were similar irrespective of patients’ age, gender or COPD severity.

Additionally, it has been previously shown that at pressure drop of up to 4 kPa (equivalent to 41 cmH2O), patients are able to inhale comfortably through a DPI [27]. In this study, a pressure drop of 41 cmH2O and 36 cmH2O at PIF was achieved by patients of older age (≥75 years) and patients with very severe COPD, respectively, when using the Breezhaler® inhaler compared with either the Ellipta® or the HandiHaler® inhalers. The inspiratory effort determined for the Breezhaler® inhaler was less than 4 kPa at any estimated flow rate [28], indicating that patients inhaled most comfortably when using this device.

The inspiratory efforts required by patients’ becomes an important consideration in treatment decisions, when a minimum inhalation flow through a specific DPI is critical for efficient de-aggregation of drug particles [26] which is not the case with the low resistance DPIs like Breezhaler® inhaler. Previously published studies for glycopyrronium and indacaterol via Breezhaler® demonstrated there was consistent dose delivery performance from Breezhaler® using airflow rates between 50 and 100 L/min. In our present study also in overall population and in the sub-groups, by COPD severity or age or gender, all patients were able to generate PIF rates of at least 54 L/min through Breezhaler, suggesting consistent dose delivery performance from Breezhaler® irrespective of patients’ age, gender or COPD severity.

Some COPD patients may have difficulty with the effort required to generate sufficient inspiratory flow through a high-resistance inhaler because of loss of muscle mass and/or COPD severity [29, 30]. Therefore, when prescribing an inhalation treatment, it is important to establish whether patients can inhale comfortably through the inhaler device to be used to deliver that treatment. The ease with which patients are able to inhale through an inhaler is an important aspect of COPD management. Our results show that patients, irrespective of their COPD severity, age and gender, were able to inhale with least inspiratory effort (pressure drop) and generate highest PIF values when inhaling through the Breezhaler® inhaler compared with either the Ellipta® or the HandiHaler® inhalers. Although, we observed a slightly aberrant pattern with higher PIF values in patients aged ≥75 years (105 L/min) than that in patients aged 65–74 years (101 L/min), this could be due to comparatively less number of patients analyzed in ≥75 years age group (n = 46 versus n = 24 in 65–74 years) in the study.

The strengths of this study include minimization of inter-subject variability as measures like PIF or pressure drop are objective physical and mathematical measures, which may not be affected by prior use or experience of the patients unlike handling, preference or other measures. Furthermore random allocation and cross over design further minimizes any potential sequence bias. This study had certain limitations: the pharmacological effect of drug inhalation was not studied because this study design required multiple inhalations through the inhalers over short period of time and the PIF values may not reflect a non-research setting such as at home or during an exacerbation.

Information on the comparative inhalational flow rates and inhalation profiles from the studies DPIs and across the various studies COPD patients sub-groups would allow physicians to make informed decisions in selecting the right inhaler for the patient. Further studies would be useful to establish the generalizability of these results.

**Conclusion**

The results showed that mean PIF values increased and mean pressure drop values at the PIF decreased with decreasing airflow resistance of the inhalers. Patients with COPD were able to inhale with the least inspiratory effort and generate the highest mean PIF value through the Breezhaler® inhaler when compared with the Ellipta® inhaler and the HandiHaler® inhaler. The results were similar irrespective of patients’ COPD severity, age or gender.

**Additional file**

Additional file 1: List of Independent Ethics Committees. (DOCX 14 kb)
The authors declared that they have no competing interests.

Competing interests prior to performing any study related assessment.

The study was conducted according to the ethical principles of the drafting and revising of the manuscript. All authors read and approved the LW, PA, JD, TG, BA, MCM, AVP, PG have contributed towards data analysis, authors.

Funding

The study was sponsored by Novartis Pharma AG.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LW, PA, JD, TG, BA, MCM, AVP, PG have contributed towards data analysis, drafting and revising of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

The study was conducted according to the ethical principles of the Declaration of Helsinki. The study protocol was reviewed by the institutional review boards and ethics committees for each center (list included in Additional file 1). Written informed consent was obtained from each patient prior to performing any study related assessment.

Competing interests

The authors declared that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 2 Instituto Ave Pulmo, Fundación Enfisema, Mar del Plata, Argentina. 3 Novartis Pharma AG, Basel, Switzerland. 4 Novartis Ireland Limited, Dublin, Ireland. 5 Novartis Pharmaceuticals Corporation, San Carlos, California, USA. 6 Novartis Argentina SA, Buenos Aires, Argentina.

Received: 4 January 2018 Accepted: 25 May 2018

Published online: 14 June 2018

References

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017.
2. Bonni M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1:9.
3. Lavorini F, Mannini C, Chellini E, Fontana GA. Optimising inhaled pharmacotherapy for elderly patients with chronic obstructive pulmonary disease: the importance of delivery devices. Drugs Aging. 2016;33(7):461–74.
4. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, allergy, and immunology. Chest. 2005;127(1):335–71.
5. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI Respir Med. 2020;9(5):496–500.
6. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005;50(10):1304–12. discussion 1312.
7. Pedersen S, Steffensen G. Fenoterol powder inhaler technique in children: influence of inspiratory flow rate and breath-holding. Eur J Respir Dis. 1986;68(3):207–14.
8. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–12.
9. Clark AR, Hollingsworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110.
10. Dereckers JH, Singh D, Pavkov R. Inspiratory flow profiles generated by patients with COPD through the Breezhaler® inhaler and other marketed dry powder inhalers. Poster presented at the Am J Respir Crit Care Med, American Thoracic Society International Conference, May 15–20, 2015, Denver, CO, USA, 2015. Vol. 191.
11. Colthorpe P, Voshar T, Kielickus T, Cuoghi E, Jansen I. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycochryponium. J Drug Assess. 2013;1(11):1–6.
12. Mueller S, Haefelini B, S. E. Comparison of performance characteristics for Foradil Aerolizer® and Foradil Concept1 (a new single dose dry powder inhaler) at different test flow rates. Resp Drug Deliv. 2008;3:67–67.
13. Pavkov R, Singh D. Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. Resp Drug Deliv. 2008;3:683–6.
14. Kutter A, Dimke T. A novel biophysical simulation model of drug deposition implemented to predict and optimize QtA149 delivery to the lungs. American Thoracic Society International Conference, San Diego, CA, US, 16 May–21 May, 2014. Vol Abs A3038.
15. Pavkov R, Mueller S, Feibich K, Singh D, Stowasser F, Pignatelli G, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527–33.
16. Mollard M, Raherison C, Lignon S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 3935 patients. Eur Respir J. 2017;49(2).
17. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadaday D, Dereckers J, et al. Delivery characteristics and patients’ handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–63.
18. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014.
19. Chodosh S, Flanders JS, Nesten S, Serby CW, Hochrainer D, Wette TJ. Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14(3):309–15.
20. Phillip Krüger BE, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J. 2014;2014(44):4635.
21. Darba J, Ramirez G, Sicras A, Francoli P, Torvinen S, Sanchez-de la Rosa R. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:2335–45.
22. Hira D, Koide H, Nakamura S, Okada T, Ishizeki K, Yamaguchi M, et al. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One. 2018;13(2):e0193082.
23. Ibrahim M, Verma R, Garcia-Contrares L. Inhalation drug delivery devices: technology update. Med Devices (Auck). 2015;8:131–9.
24. Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhalant-specific inhalation profiles through the ELLIPTA(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486–97.
25. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–9.
26. Price D, Crystyn H. Concept review of dry powder inhalers: correct interpretation of published data. Multidiscip Respir Med. 2015;10:36.
27. Behra SR, Larson J, Kippax P, Stewart P, Morton DA. Insight into pressure drop dependent efficiencies of dry powder inhalers. Eur J Pharm Sci. 2012;46(3):142–8.
28. Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat(R) inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2015;10:2355–67.
29. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18–25.
30. Brennan WA, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir Med. 2005;99(1):97–102.